Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on acquisition of the Frösunda Group
Mandate

Vinge advises on acquisition of the Frösunda Group

May 03, 2010

Vinge has advised HgCapital in connection with the acquisition of Frösunda LLS AB and its subsidiaries from Polaris Private Equity Fund II and certain minority shareholders. HgCapital’s team was led by Carl Harring.

The transaction is subject to competition law clearance.

The Frösunda Group is the leading private sector personal care provider to people with functional impairments in Sweden with operations in approximately 40 cities and the group has approximately 3700 employees.

Vinge’s team was led by Malin Leffler (responsible partner) and Martin Hall (project manager) and included associates Jonas Bergström, Johan Cederblad, Daniel Unger, Åsa Gotthardsson, Mårten Svensson and Adam Weissbach. Partner Mikael Ståhl was responsible for acquisition financing, assisted by associates Louise Brorsson Salomon and Sofia Graflund. Peter Alstergren provided competition law advice.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025